Universal Beteiligungs und Servicegesellschaft mbH Acquires New Position in Evolent Health, Inc (NYSE:EVH)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Evolent Health, purchasing 41,401 shares valued at approximately $392,000 during the first quarter.
• Other institutional investors also increased their stakes, with Allianz Asset Management lifting its holdings by 48.9% and Hussman Strategic Advisors raising its position by 66.7% in the same period.
• Evolent Health reported quarterly earnings of $0.06 per share, missing estimates, and had a revenue of $483.65 million, which was below the consensus estimate of $460.15 million.

Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Evolent Health, Inc (NYSE:EVH - Free Report) during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 41,401 shares of the technology company's stock, valued at approximately $392,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Allianz Asset Management GmbH lifted its holdings in shares of Evolent Health by 48.9% during the 1st quarter. Allianz Asset Management GmbH now owns 68,541 shares of the technology company's stock valued at $649,000 after buying an additional 22,514 shares during the last quarter. Hussman Strategic Advisors Inc. raised its position in Evolent Health by 66.7% during the first quarter. Hussman Strategic Advisors Inc. now owns 105,000 shares of the technology company's stock valued at $994,000 after acquiring an additional 42,000 shares in the last quarter. Signaturefd LLC raised its position in Evolent Health by 400.6% during the first quarter. Signaturefd LLC now owns 7,043 shares of the technology company's stock valued at $67,000 after acquiring an additional 5,636 shares in the last quarter. Rock Point Advisors LLC lifted its stake in Evolent Health by 37.6% in the first quarter. Rock Point Advisors LLC now owns 824,535 shares of the technology company's stock valued at $7,808,000 after acquiring an additional 225,396 shares during the last quarter. Finally, 49 Wealth Management LLC bought a new stake in Evolent Health in the first quarter worth approximately $185,000.

Evolent Health Price Performance

Shares of Evolent Health stock opened at $9.97 on Monday. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.98 and a quick ratio of 0.98. The company has a market cap of $1.17 billion, a PE ratio of -8.11 and a beta of 0.82. The firm has a fifty day moving average price of $9.73 and a two-hundred day moving average price of $9.66. Evolent Health, Inc has a fifty-two week low of $7.06 and a fifty-two week high of $33.63.

Evolent Health (NYSE:EVH - Get Free Report) last released its earnings results on Thursday, May 8th. The technology company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.08 by ($0.02). Evolent Health had a negative net margin of 4.54% and a positive return on equity of 3.64%. The company had revenue of $483.65 million during the quarter, compared to the consensus estimate of $460.15 million. During the same quarter in the previous year, the business posted $0.34 EPS. The firm's quarterly revenue was down 24.4% on a year-over-year basis. Analysts expect that Evolent Health, Inc will post 0.08 EPS for the current year.

Analyst Ratings Changes

EVH has been the subject of a number of recent research reports. Needham & Company LLC reiterated a "buy" rating and issued a $15.00 price objective on shares of Evolent Health in a report on Tuesday, May 13th. UBS Group upped their price target on Evolent Health from $14.00 to $15.00 and gave the stock a "buy" rating in a research note on Friday, May 9th. JMP Securities reissued a "market outperform" rating and issued a $13.00 price objective on shares of Evolent Health in a research note on Friday, June 20th. Finally, Truist Financial boosted their target price on Evolent Health from $14.00 to $16.00 and gave the stock a "buy" rating in a report on Thursday, July 17th. One equities research analyst has rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $17.93.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.